Investigational drug · Phase 3
AK117
Not approved by FDA. In 14 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
14
12 still active
All registered trials
19
Any phase or sponsor naming "AK117"
First trial start
2021
Jun 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- Akeso14
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK117", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Advanced Malignant Tumors
- ACUTE MYELOID LEUKEMIA; AML
- Higher-risk Myelodysplastic Syndromes
- Metastatic Colorectal Cancer
- Acute Myeloid Leukemia
- Pancreatic Cancer
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Head and Neck Squamous Cell Carcinoma
- Metastatic Triple-negative Breast Cancer
- Locally Advanced Triple-negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Head and neck cancer · Acute myeloid leukemia · Oncology · Hematology and blood cancers · Rare and genetic disease · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AK117" as an intervention, largest first.
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerPivotal-lookingRecruiting
AkesoIndustry
NCT06953999 · 999 participants (planned) · Start Jun 11, 2025 · Primary completion May 14, 2027
Drug: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine; Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine and 1 more · For: Pancreatic Cancer
Sites: Harbin, China; Shanghai, China; Hangzhou, China
- Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHNPivotal-lookingRecruiting
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
NCT07264075 · 780 participants (planned) · Start May 5, 2026 · Primary completion May 2030
Drug: Ivonescimab 10 mg/kg; Ligufalimab and 1 more · For: Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Sites: Le Havre, France
- A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)Pivotal-lookingRecruiting
AkesoIndustry
NCT06601335 · 510 participants (planned) · Start Oct 30, 2024 · Primary completion Jan 2027
Drug: AK117 in combination with AK112; Placebo in combination with Pembrolizumab · For: Head and Neck Squamous Cell Carcinoma
Sites: Wuhan, China; Chengdu, China
AkesoIndustry
NCT06642792 · 280 participants (planned) · Start Jan 17, 2025 · Primary completion Nov 2027
Drug: AK129; AK117 · For: Classic Hodgkin Lymphoma
Sites: Beijing, China
- A Study of AK112 With or Without AK117 in Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
AkesoIndustry
NCT05382442 · 254 participants (planned) · Start Jun 27, 2022 · Primary completion May 15, 2026
Drug: AK112; AK117 and 5 more · For: Metastatic Colorectal Cancer
Sites: Los Angeles, California; Murrieta, California; Fairfax, Virginia · 4 sites in all
- A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid LeukemiaPivotal-lookingNot yet recruiting
AkesoIndustry
NCT06387420 · 180 participants (planned) · Start Apr 29, 2024 · Primary completion Apr 2026
Drug: AK117; Azacitidine and 1 more · For: ACUTE MYELOID LEUKEMIA; AML
Sites: Tianjin, China
- A Study of Ivonescimab in First-Line ES-SCLCPivotal-lookingRecruiting
AkesoIndustry
NCT07245446 · 180 participants (planned) · Start Oct 29, 2025 · Primary completion Dec 2027
Drug: Ivonescimab; Cadonilimab and 3 more · For: Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sites: Beijing, China; Xi'an, China; Shanghai, China
- A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsActive, not recruiting
AkesoIndustry
NCT05229497 · 154 participants (planned) · Start May 4, 2022 · Primary completion Dec 31, 2026
Drug: AK112; AK117 and 4 more · For: Advanced Malignant Tumors
Sites: Hangzhou, China
AkesoIndustry
NCT05214482 · 154 participants · Start Jan 22, 2022 · Primary completion Nov 20, 2025
Drug: AK112; AK117 and 1 more · For: Advanced Malignant Tumors
Sites: Hangzhou, China
- A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic SyndromeActive, not recruiting
AkesoIndustry
NCT04900350 · 136 participants · Start Jun 18, 2021 · Primary completion Sep 2025
Drug: AK117; Azacitidine · For: Myelodysplastic Syndrome
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma.
Qin L, Li Y, Zeng R, et al. · Hum Vaccin Immunother 2024
- Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity.
Qu T, Zhong T, Pang X, et al. · J Immunother Cancer 2022
Also in development for Advanced Malignant Tumors
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
- IAP0971Phase 23 trials
SUNHO(China)BioPharmaceutical CO., Ltd. · Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer
- IBB0979Phase 22 trials
SUNHO(China)BioPharmaceutical CO., Ltd. · Small Cell Lung Cancer, Advanced Malignant Tumors
- JMT108Phase 22 trials
Shanghai JMT-Bio Inc. · Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors, Advanced Malignant Tumors
- LBL-033Phase 21 trial
Nanjing Leads Biolabs Co.,Ltd · Advanced Malignant Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.